Cornblath M
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA.
Acta Paediatr Jpn. 1997 Apr;39 Suppl 1:S7-11.
Since 1911, blood sugars have been measured in newborn infants. Significant neonatal hypoglycemia was first reported in 1937. In 1959, the report of transient symptomatic neonatal hypoglycemia generated worldwide reports. This, along with the ongoing advances in studies of energy metabolism, thermal control and oxygen requirements, led to the first conference on Energy and Carbohydrate Metabolism in the newborn in Tokyo, 1965. Subsequently, a number of hypoglycemia syndromes were discovered. Concurrently, pre-, peri- and neonatal care changed dramatically with the survival or very tiny and very sick newborns. These advances in care made previously derived statistical definitions of hypoglycemia irrelevant. New functional definitions are needed to define abnormal glucose concentrations. Significant hypoglycemia is a continuum of low glucose concentrations of varied duration and severity. Its impact depends upon other risk factors as well. In addition, new hypoglycemic syndromes have appeared. These include deficiencies of blood-brain glucose transporters, the association of hyperinsulinemic hypoglycemia with isoimmune thrombocytopenia and a variety of acyl CoA dehydrogenase deficiencies. Concurrently, carbohydrate disorders in infancy appear to be changing. Neonatal diabetes mellitus, previously transient and benign, now shows a high frequency of recurrence and remaining as a permanent condition. Idiopathic ketotic hypoglycemia of infancy has disappeared in the USA. Familial hyperinsulinemic hypoglycemic syndromes of infancy appear to have a good prognosis, respond to medical intervention and have had their genetic defect localized to a specific gene. Current advances promise reliable bedside techniques to measure central nervous system function, cerebral blood flow, endocrine hormones and receptors as well as glucose transporters and specific genetic defects. These data, when correlated with plasma glucose concentrations and central nervous system function and development, should provide a better understanding of the impact of prolonged and profound hypoglycemia on long-term outcome.
自1911年起,人们就开始测量新生儿的血糖。1937年首次报告了严重的新生儿低血糖症。1959年,关于短暂性症状性新生儿低血糖症的报告引发了全球范围的报道。这一情况,连同能量代谢、体温控制和氧气需求研究的不断进展,促成了1965年在东京召开的首届新生儿能量与碳水化合物代谢会议。随后,发现了许多低血糖综合征。与此同时,随着极小和重病新生儿的存活,产前、围产期和新生儿护理发生了巨大变化。这些护理方面的进展使得先前得出的低血糖统计定义变得不再适用。需要新的功能定义来界定异常血糖浓度。严重低血糖是持续时间和严重程度各异的低葡萄糖浓度的连续过程。其影响还取决于其他风险因素。此外,还出现了新的低血糖综合征。这些包括血脑葡萄糖转运体缺陷、高胰岛素血症性低血糖与同种免疫性血小板减少症的关联以及多种酰基辅酶A脱氢酶缺陷。与此同时,婴儿期的碳水化合物紊乱情况似乎正在发生变化。以前短暂且良性的新生儿糖尿病,现在复发频率很高,并会持续成为一种永久性病症。美国婴儿特发性酮症性低血糖症已消失。婴儿家族性高胰岛素血症性低血糖综合征似乎预后良好,对医学干预有反应,并且其基因缺陷已定位到特定基因。当前的进展有望带来可靠的床边技术,用于测量中枢神经系统功能、脑血流量、内分泌激素和受体以及葡萄糖转运体和特定基因缺陷。这些数据与血浆葡萄糖浓度以及中枢神经系统功能和发育相关联时,应能更好地理解长期严重低血糖对长期预后的影响。